2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-171255
    KRAS G12D inhibitor 26
    		Inhibitor
    KRAS G12D inhibitor 26 is a modulator of Kras, targeting Kras(G12D) with an IC50 ≤ 100 nM.
    KRAS G12D inhibitor 26
  • HY-N8387
    Neogrifolin
    		Inhibitor
    Neogrifolin is an inhibitor of KRAS. Neogrifolin suppress KRAS expression in human colon cancer cells. Neogrifolin has anti-cell viability activity against HeLa, SW480 and HT29 cells wih IC50s of 24.3, 34.6, and 30.1 μM, respectively.
    Neogrifolin
  • HY-122079
    NSC1011
    NSC1011 is a potent Ras converting enzyme 1 endoprotease (Rce1) inhibitor with an IC50 value of 6.9 µM for HsRce1 (crystal structure of the human Rce1). NSC1011 induces mislocalizing EGFR-H-Ras, EGFR-N-Ras, and EGFR-K-Ras.
    NSC1011
  • HY-159473
    K-Ras-IN-3
    		Inhibitor
    K-Ras-IN-3 (compound 3) is a potent GDP-KRAS G12V inhibitor with an IC50 value of 0.371 nM. K-Ras-IN-3 has the potential for the research of cancer.
    K-Ras-IN-3
  • HY-164365
    PROTAC K-Ras Degrader-2
    		Degrader
    PROTAC K-Ras degrader-2 (compound 48) is a pan-KRAS-mutant PROTAC degrader with an IC50 of ≤200 nM for KRAS G12V/RAF1. PROTAC K-Ras degrader-2 degrades SW620 KRAS G12D with a DC50 of ≤200 nM. PROTAC K-Ras degrader-2 inhibits cell growth of SW620 3D cell with an IC50 of ≤20 nM. (Pink: KRAS inhibitor-30 (HY-164366)).
    PROTAC K-Ras Degrader-2
  • HY-134299
    8-CPT-cAMP-AM
    		Activator
    8-CPT-cAMP-AM is a highly membrane-permeant analogue of signal molecule cAMP. 8-CPT-cAMP-AM is an activator of cAMP- and cGMP-dependent protein kinases and of Epac (exchange protein activated by cAMP).
    8-CPT-cAMP-AM
  • HY-162439
    pan-KRAS-IN-6
    		Inhibitor
    pan-KRAS-IN-6 (compound 12) is a potent pan KRAS inhibitor with IC50 values of 9.79 nM (Kras G12D) and 6.03 nM (Kras G12V).
    pan-KRAS-IN-6
  • HY-145018
    KRAS G12C inhibitor 21
    		Inhibitor
    KRAS G12C inhibitor 21 is a KRAS G12C inhibitor extracted from patent WO2021219090A1, example 7.
    KRAS G12C inhibitor 21
  • HY-143590
    KRAS G12C inhibitor 37
    		Inhibitor
    KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65).
    KRAS G12C inhibitor 37
  • HY-W549903
    p67phox-IN-1
    		Inhibitor
    p67phox-IN-1 (Formula IIIa Compound) is an inhibitor targeting the interaction between Rac GTPase and p67phox protein.
    p67phox-IN-1
  • HY-163489
    pan-KRAS-IN-15
    		Inhibitor
    pan-KRAS-IN-15 (compound 58) is a pan-KRAS inhibitor. pan-KRAS-IN-15 can be used in pancreatic cancer research.
    pan-KRAS-IN-15
  • HY-P2157
    Ras Inhibitory Peptide
    		Inhibitor
    Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity.
    Ras Inhibitory Peptide
  • HY-153412
    KRAS inhibitor-22
    		Degrader
    KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of K-Ras. KRAS inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research.
    KRAS inhibitor-22
  • HY-153881
    KRAS G12C degrader-1
    KRAS G12C degrader-1 (Compound 283) is a potent KRAS G12C degrader (DC50: < 100 nM) for cancer research. KRAS G12C degrader-1 is a chaperone (HSP90)-mediated protein degrader (CHAMPs).
    KRAS G12C degrader-1
  • HY-146543
    KRAS inhibitor-13
    		Inhibitor
    KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC50s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-13
  • HY-142946
    KRAS G12C inhibitor 44
    		Inhibitor
    KRAS G12C inhibitor 44 (compound 54) is a potent and orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC50s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo.
    KRAS G12C inhibitor 44
  • HY-153989
    SOS1-IN-16
    		Inhibitor
    SOS1-IN-16 (Comp 54) is a selective inhibitor of SOS1 with an IC50 of 7.2 nM. SOS1-IN-16 has inhibitory activity of CYP3A4 when using testosterone as a substrate, with an IC50 of 8.9μM. SOS1-IN-16 can be used for cancer research.
    SOS1-IN-16
  • HY-147633
    KRAS G12C inhibitor 52
    		Inhibitor
    KRAS G12C inhibitor 52 (Compound 7) is a KRAS G12C inhibitor.
    KRAS G12C inhibitor 52
  • HY-146432
    Antitumor agent-60
    		Inhibitor
    Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model.
    Antitumor agent-60
  • HY-163880
    EGFR-IN-119
    		Inhibitor
    EGFR-IN-119 (Compound 5l) is an inhibitor for EGFR with an IC50 of 84.3 nM. EGFR-IN-119 inhibits the cytotoxicity in lung cancer cell A549 with an IC50 of 1.34 μM. EGFR-IN-119 downregulates the expressions of EGFR, KRAS, and MAP2K genes, exhibits antioxidant activity through reduction of reactive oxygen species (ROS), and hyperpolarizes the mitochondrial membrane potential.
    EGFR-IN-119
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.